Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A 5-year follow-up of the KEYNOTE-826 trial confirms that adding pembrolizumab to chemotherapy nearly doubles long-term survival rates in advanced cervical cancer. Patients on pembrolizumab had a median overall survival of 26.4 months vs. 16.8 months on placebo, with 5-year survival rates of 33% vs. 18%. The findings cement pembrolizumab plus chemo as a standard-of-care option for this patient population.
A 5-year extended follow-up of the phase 3 KEYNOTE-826 trial has confirmed that adding pembrolizumab to chemotherapy (with or without bevacizumab) delivers durable, long-term survival benefits for patients with previously untreated persistent, recurrent, or metastatic cervical cancer. The results, published in JAMA Oncology, reinforce pembrolizumab-based therapy as a standard-of-care option for this challenging patient population.
The trial enrolled 617 women, with a median age of 51 years. Patients received pembrolizumab or placebo every 3 weeks for up to 35 cycles alongside platinum-based chemotherapy. The survival advantage was consistent across both the overall population and those with PD-L1 combined positive scores (CPS) of at least 1.
By the Numbers:
Why it matters: Advanced cervical cancer carries a poor prognosis, and durable 5-year data are rare in this setting. These results provide clinicians with strong, long-term evidence to support pembrolizumab-based regimens as a go-to first-line treatment.
